222 related articles for article (PubMed ID: 29752752)
1. Long-term safety and efficacy of the novel β
Yoshida M; Kakizaki H; Takahashi S; Nagai S; Kurose T
Int J Urol; 2018 Jul; 25(7):668-675. PubMed ID: 29752752
[TBL] [Abstract][Full Text] [Related]
2. Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.
Mitcheson HD; Samanta S; Muldowney K; Pinto CA; Rocha BA; Green S; Bennett N; Mudd PN; Frenkl TL
Eur Urol; 2019 Feb; 75(2):274-282. PubMed ID: 30661513
[TBL] [Abstract][Full Text] [Related]
3. Vibegron, a Novel Potent and Selective β
Yoshida M; Takeda M; Gotoh M; Nagai S; Kurose T
Eur Urol; 2018 May; 73(5):783-790. PubMed ID: 29366513
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of novel β
Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Hashimoto K; Minemura K
Int J Urol; 2019 Mar; 26(3):369-375. PubMed ID: 30557916
[TBL] [Abstract][Full Text] [Related]
5. Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR).
Staskin D; Frankel J; Varano S; Shortino D; Jankowich R; Mudd PN
J Urol; 2021 May; 205(5):1421-1429. PubMed ID: 33356445
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study.
Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Minemura K
BJU Int; 2020 May; 125(5):709-717. PubMed ID: 31991511
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of Vibegron in treating overactive bladder: A systematic review and pooled analysis of randomized controlled trials.
Shi H; Chen H; Zhang Y; Cui Y
Neurourol Urodyn; 2020 Jun; 39(5):1255-1263. PubMed ID: 32421908
[TBL] [Abstract][Full Text] [Related]
9. International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR.
Staskin D; Frankel J; Varano S; Shortino D; Jankowich R; Mudd PN
J Urol; 2020 Aug; 204(2):316-324. PubMed ID: 32068484
[TBL] [Abstract][Full Text] [Related]
10. Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder.
Su S; Liang L; Lin J; Liu L; Chen Z; Gao Y
Medicine (Baltimore); 2021 Feb; 100(5):e23171. PubMed ID: 33592817
[TBL] [Abstract][Full Text] [Related]
11. Vibegron (Gemtesa) for overactive bladder.
Med Lett Drugs Ther; 2021 May; 63(1623):67-69. PubMed ID: 33976098
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States.
Chen JV; Klein TM; Nesheim J; Mudd PN
J Med Econ; 2022; 25(1):1092-1100. PubMed ID: 35993729
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular safety of vibegron, a new β3-adrenoceptor agonist, in older patients with overactive bladder: Post-hoc analysis of a randomized, placebo-controlled, double-blind comparative phase 3 study.
Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Minemura K
Neurourol Urodyn; 2021 Aug; 40(6):1651-1660. PubMed ID: 34139038
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison.
Kennelly MJ; Rhodes T; Girman CJ; Thomas E; Shortino D; Mudd PN
Adv Ther; 2021 Nov; 38(11):5452-5464. PubMed ID: 34537953
[TBL] [Abstract][Full Text] [Related]
15. Editorial Comment from Dr Chapple to Long-term safety and efficacy of the novel β
Chapple CR
Int J Urol; 2018 Jul; 25(7):677. PubMed ID: 29869398
[No Abstract] [Full Text] [Related]
16. Editorial Comment from Dr Yamanishi to Long-term safety and efficacy of the novel β
Yamanishi T
Int J Urol; 2018 Jul; 25(7):676. PubMed ID: 29862577
[No Abstract] [Full Text] [Related]
17. Vibegron: a β
Paton DM
Drugs Today (Barc); 2021 Aug; 57(8):507-517. PubMed ID: 34405208
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study.
Varano S; Staskin D; Frankel J; Shortino D; Jankowich R; Mudd PN
Drugs Aging; 2021 Feb; 38(2):137-146. PubMed ID: 33469832
[TBL] [Abstract][Full Text] [Related]
19. Additive effects of intravenous and intravesical application of vibegron, a β
Furuta A; Suzuki Y; Igarashi T; Koike Y; Kimura T; Egawa S; Yoshimura N
Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2073-2080. PubMed ID: 32556396
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of vibegron in patients with overactive bladder: Multicenter prospective study of real-world clinical practice in Japan, SCCOP study 19-01.
Tachikawa K; Kyoda Y; Fukuta F; Kobayashi K; Masumori N
Low Urin Tract Symptoms; 2022 Mar; 14(2):109-116. PubMed ID: 34713579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
